The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Aortoiliac Occlusive Disease, Peripheral Arterial Disease
About this trial
This is an interventional treatment trial for Aortoiliac Occlusive Disease
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years at time of informed consent signature Informed Consent Form (ICF) is signed by the subject Subject can comply with protocol requirements, including follow-up Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5) Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies) Patient has: Unilateral or bilateral single or multiple lesions (>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm Patient has a sufficient (<50% stenotic) common femoral artery and at least one sufficient (<50% stenotic) femoral artery (deep or superficial). Patient has at least one sufficient (<50% stenotic) infrapopliteal run-off vessel. Exclusion Criteria: Life expectancy <1 year Patient is pregnant at time of informed consent. Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin). Patient has severe chronic renal insufficiency (serum creatinine level > 2.5mg/dL) and not undergoing hemodialysis. Patient has evidence of a systemic infection. Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use. Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure). Patient has previous stenting in the iliac arteries. Patient has previous surgical bypass in the target limb. Patient is currently participating in another investigative clinical study unless received written approval by the sponsor. Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery. Patient has an abdominal aortic artery lesion or aneurysm. Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament. Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery). Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization).
Sites / Locations
- North Suburban Medical Center
- University of Pennsylvania
- The University of Texas Southwestern Medical Center
- Texas Tech University Health Science Center
- Krankenhaus der Barmherzigen Brüder
- Rijnstate Hospital
- Auckland City Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
VBX Device Group
BMS Control Group
Subject in this group will receive treatment with the GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
Subjects in this group will receive treatment with a commercially available bare metal stent (BMS) that is approved for treatment of the disease